Aerovate Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch AVTE and buy or sell other stocks, ETFs, and their options commission-free!About AVTE
Jade Biosciences, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.
CEOTom Frohlich, MBA
CEOTom Frohlich, MBA
Employees30
Employees30
HeadquartersWaltham, Massachusetts
HeadquartersWaltham, Massachusetts
Founded2018
Founded2018
Employees30
Employees30
AVTE Key Statistics
Market cap319.74M
Market cap319.74M
Price-Earnings ratio-0.30
Price-Earnings ratio-0.30
Dividend yield—
Dividend yield—
Average volume185.14K
Average volume185.14K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$100.28
52 Week high$100.28
52 Week low$6.57
52 Week low$6.57
Stock Snapshot
As of today, Aerovate Therapeutics(AVTE) shares are valued at $9.80. The company's market cap stands at 319.74M, with a P/E ratio of -0.30.
On 2025-11-05, Aerovate Therapeutics(AVTE) stock opened at —, reached a high of —, and a low of —.
Aerovate Therapeutics(AVTE) shares are trading with a volume of 0, against a daily average of 185.14K.
In the last year, Aerovate Therapeutics(AVTE) shares hit a 52-week high of $100.28 and a 52-week low of $6.57.
In the last year, Aerovate Therapeutics(AVTE) shares hit a 52-week high of $100.28 and a 52-week low of $6.57.
People also own
Based on the portfolios of people who own AVTE. This list is generated using Robinhood data, and it’s not a recommendation.